Rivaroxaban
Top View
- Study Protocol
- Combining Antiplatelets and Anticoagulants Example
- Management of Bleeding in Patients Treated with Direct Oral Anticoagulants Marcel Levi1,2
- COVID-19 Vaccine Astrazeneca (Other Viral Vaccines) EPITT No:19683
- Rivaroxaban: a Fully-Subsidised Oral Anticoagulant
- Clinical Protocol
- IMPORTANT DRUG WARNING XARELTO® (Rivaroxaban) Film
- Guidance on Safe Switching of Warfarin to DOAC
- Prescriptions of Direct Oral Anticoagulants in Patients Admitted
- Bericht ATC-Code B01: Antithrombotische Mittel
- Rivaroxaban and Apixaban for DVTVTE Prophylaxis
- Rivaroxaban) Safely and Effectively
- A New Oral Anticoagulant in Cats by AMY
- Guidelines for Management of Patients on Rivaroxaban (Xarelto) Or Apixaban (Eliquis)
- Anticoagulation and Antiplatelet Update: a Case Based Approach
- Anti-Platelet and Anti-Coagulant Prescriptions and Breast Cancer Recurrence: a Danish Nationwide Prospective Cohort Study
- Rivaroxaban Handout – UC Davis 2013
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019